Cure TV

Dr. Patrick Wen discussed with CURE how Modeyso treats diffuse midline glioma, and what unmet needs remain for patients now that the therapy is available.

Dr. Alexander Spira explained the difference between a clinical trial and a real-world study in a CURE interview for patients with lung cancer.

Ibtrozi may become the new standard for ROS1-mutated lung cancer, with phase 2 data showing safer, longer-lasting benefits for patients.

Targeted therapies have changed non-small cell lung cancer care, but new side effects, like weight gain, are emerging, says Dr. Lorenzo Belluomini.

Dr. Jacob A. Sands shares how patients with lung cancer can interpret clinical trial results and how these findings translate to treatment decisions.

Dr. David A. Taub sat down with CURE for an interview in honor of Prostate Cancer Awareness Month, observed annually each September.

CURE spoke with chief medical officer Gwen Nichols and partner Suleika Jaouad about the inclusive rebranding.

After years of chronic cough and misdiagnosed infections, a 2016 stage 4 ALK-positive lung cancer diagnosis led to targeted therapy that has helped since.

Heather Ann Yonker, emphasizes the importance of food safety practices for patients with cancer, particularly those with weakened immune systems.

Dr. Prithviraj Bose discussed the current treatment landscape for myeloproliferative neoplasms, a group of rare blood cancers; he focused on myelofibrosis.

Patients need long-term monitoring after gastrointestinal stromal tumor surgery, with some requiring extra treatment or genetic testing to lower recurrence risk.

Dr. Christina Cho highlights the Adult Stem Cell Transplant and Cellular Therapy Program for its innovative research and compassionate, multidisciplinary team.

After receiving a breast cancer diagnosis at 29, Amanda Davis wants other young adults who are patients to know that “brighter days are coming.”

Kidney cancer care has seen advances over the past few decades, reflecting both improved diagnostic capabilities and less invasive treatment approaches.

Obtaining an accurate diagnosis is a crucial first step in kidney cancer care, according to Dr. Shuanzeng “Sam” Wei of Fox Chase Cancer Center.

Being diagnosed with a rare cancer like GIST can be overwhelming, highlighting the need for support networks, says Dr. Rosario Ligresti.

Dr. Prithviraj Bose discusses how patients with myelofibrosis can better understand their options and access the most up-to-date advancements in care.

Dr. Joshua K. Sabari sat down with Terri Conneran at the 2025 World Conference on Lung Cancer for a conversation on the importance of biomarker testing.

Dr. Rosario Ligresti explained that while many GISTs are found incidentally, larger tumors may cause anemia, bleeding or swallowing issues.

Dr. Geoffrey Liu discussed findings from the phase 2 TRUST-II clinical trial evaluating Ibtrozi (taletrectinib) among patients with ROS1-positive non-small cell lung cancer.

Dr. Joshua Sabari spoke with advocate Chris Conneran on his journey from caregiver to champion for KRAS-mutant cancer patients and families.

As the prostate cancer treatment landscape continues to evolve, understanding the risks and benefits of each approach is critical for patients.

Dr. Josh Sabari and Max Doppelt explore challenges in trial enrollment and the potential of emerging therapies to offer hope for patients diagnosed today.

This guide for newly diagnosed patients provides key information to help you understand your options and have informed conversations with your oncologist.

Early-stage gynecologic cancer is confined to its original site and often treatable; diagnosis, surgery, and new therapies improve outcomes.

Dr. Thomas Jankowski explained that THIO, a telomerase inhibitor, is being studied with Libtayo to help overcome resistance in advanced lung cancer.

Advances are reshaping treatment for small cell lung cancer, with immunotherapy and emerging options offering hope for longer survival and potential cures.

CURE spoke with Dr. Xiuning Le during the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer.